THE NEW YORK COURSE
You must be logged in to view this content.
Your download will begin after you submit this form.
This feature closed on September 30, 2020. Please contact us at email@example.com if you are seeking credit or have any questions. Thank you!
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and Mentor. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Albert Einstein College of Medicine-Montefiore Medical Center designates this live activity for a maximum of 11.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Albert Einstein College of Medicine-Montefiore Medical Center designates this activity for 11.0 nursing contact hours. Nurses should claim only credit commensurate with the extent of their participation in the activity.
Albert Einstein College of Medicine-Montefiore Medical Center designates this continuing education activity for 11 contact hours (1.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number – JA4008224-9999-20-005-L02-P Type of Activity: Knowledge-Based
The curriculum offered at this activity is designed to meet the needs of Infectious Disease Physicians, Hepatologists, Gastroenterologists, Family Physicians, Nurse Practitioners, Physician Assistants, Nurses, Pharmacists, and others involved in frontline HIV and Hepatitis patient care and treatment.
This advanced CME activity will provide participants with state-of-the-art information and practical guidance from internationally recognized experts on progress in managing HIV and viral hepatitis, including drug development and treatment, management of important comorbidities, and drug-drug interactions. The discussions at this meeting will allow clinicians to provide the highest quality of care in a variety of practice settings.
The primary goals of this activity are to increase each attendee’s competence to:
• Identify new antiretroviral drugs and drug combinations while exploring answers to uncertainties in treatment strategies • Determine optimal approaches to diagnosis and treatment of important co-morbidities in patients with HIV infection, such as tuberculosis, malignancies and sexually transmitted infections • Detail current and developing treatment options for managing patients with viral hepatitis and its complications, including in special populations • Examine advances as well as controversies related to the transplantation of infected organs • Evaluate approaches and expert strategies geared toward preventing care provider burnout • Detail the impact of COVID-19 on HIV treatment and efforts to end this pandemic as well as the global epidemic of HIV • Identify HIV medication-related adverse drug reactions and offer strategies on how to best manage the outcomes • Recognize the significant HIV medication-related drug interactions, and when necessary offer alternative strategies to treatment
The Conflict of Interest Disclosure Policy of Albert Einstein College of Medicine and Montefiore Medical Center requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product or device company. Any presenter who has disclosed relationships that prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present. Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States. The following individuals have reported that they do not have any relevant financial relationships with ACCME-defined commercial interests during the past 12 months:
The following individuals have reported a relevant financial relationship with ACCME-defined commercial interests during the past 12 months:
Carol A. Harris, MD, MSc* (CO-CHAIR) (PEER REVIEWER)
John F. Reinus, MD* (CO-CHAIR) (PEER REVIEWER) (PRESENTER)
Mark J. Sinnett, PharmD, FASHP*(PHARMACY REVIEWER)
Roy M. Gulick, MD**
Jeanne Marrazzo, MD, MPH
Robert S. Klein, MD* (PEER REVIEWER)
Hilda Y. Ortiz-Morales, NP, PhD* (NURSE REVIEWER)
Demetre C. Daskalakis, MD
Alexandra M. Levine, MD, MACP**
Glenn J. Treisman, MD, PHD
Richard E. Chaisson, MD** Consulting Fees for Consulting: Sanofi Ownership Interest (Spouse/Partner): Merck
Raymond T. Chung, MD* ** Contracted Research as Principal Investigator: AbbVie, Gilead, Merck, Janssen, Boehringer, Bristol-Myers Squibb, Roche
Myron S. Cohen, MD** Consulting Fees for Consulting: Merck, Gilead Contracted Research as Principal Investigator: Merck, Gilead, ViiV
Peter W. Hunt, MD** Consulting Fees for Consulting: ViiV, Biotron Fees for Non-CME/CE Services (Speaking): Gilead Contracted Research as Principal Investigator: Gilead OTHER: Drug/Placebo being donated for a clinical trial (Clinical Trial Leader)
Merck Daniel R. Kuritzkes, MD** Consulting Fees for Consulting: Gilead, GlaxoSmithKline, Merck, ViiVContracted Research as Principal Investigator: AbbVie, Gilead, Merck
Jeffrey V. Lazarus, PhD Consulting Fees for Consulting: Genfit, Gilead Sciences, GlaxoSmithKline, Intercept, Janssen Contracted Research as Principal Investigator: Gilead Sciences
Anna S. Lok, MD** Consulting Fees for Consulting: CLEAR-B, Gilead, Spring Bank, GlaxoSmithKline, TARGET Contracted Research as Principal Investigator: Bristol-Myers Squibb, Gilead, TARGET
April G. Morris, FNP-C Consulting Fees for Consulting: AbbVie, Intercept Served on the Speakers Bureau: AbbVie, Gilead Sciences
Paul E. Sax, MD Consulting Fees for Consulting: Gilead, GlaxoSmithKline, Janssen, Merck, ViiVContracted Research as Principal Investigator: Gilead, GlaxoSmithKline, ViiV
Mark S. Sulkowski, MD Consulting Fees for Consulting: AbbVie, Arbutus, AssemblyBio, Biomarin, Gilead Contracted Research as Principal Investigator: AbbVie, Allergan, AssemblyBio, Proteus Digital Health
The above faculty has indicated that their relationships will not impact their ability to present an unbiased presentation.
* Planning Committee
** Indicates the intention to reference unlabeled/unapproved uses of drugs or products in his/her presentation
+ The ACCME defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients
All planners that noted a relevant COI on their disclosure form have been paired with an independent non-conflicted peer reviewer to ensure that this activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME. All planners, peer reviewers and faculty have been checked against the FDA Debarment List. (http://www.fda.gov/ICECI/EnforcementActions/FDADebarmentList/ucm2005408.htm)
Designing For Virtual Events – Friday, August 7th, 2020 – 7 pm to 8 pm
(Webinar signup is for demonstration purposes only)
Best Practices For Virtual Exhibiting – Saturday, August 8, 2020 – 7 pm to 8 pm
(Webinar signup is for demonstration purposes only)